Lesion detection by [
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
/ chemistry
Biological Transport
Carcinoma, Renal Cell
/ diagnostic imaging
Cohort Studies
Deferoxamine
/ chemistry
Female
Fluorodeoxyglucose F18
/ metabolism
Humans
Kidney Neoplasms
/ diagnostic imaging
Male
Middle Aged
Neoplasm Metastasis
Positron Emission Tomography Computed Tomography
CAIX
Clear cell renal cell carcinoma
FDG
Girentuximab
Imaging
PET
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
29
01
2019
accepted:
02
05
2019
pubmed:
7
6
2019
medline:
24
7
2020
entrez:
8
6
2019
Statut:
ppublish
Résumé
The main objective of this preliminary analysis of the IMaging PAtients for Cancer drug selecTion (IMPACT)-renal cell cancer (RCC) study is to evaluate the lesion detection of baseline contrast-enhanced CT, [ Between February 2015 and March 2018, 42 newly diagnosed mccRCC patients with good or intermediate prognosis, eligible for watchful waiting, were included. Patients underwent CT, [ A total of 449 lesions were detected by ≥1 modality (median per patient: 7; ICR 4.25-12.75) of which 42% were in lung, 22% in lymph nodes and 10% in bone. Combined [ The addition of [
Identifiants
pubmed: 31172212
doi: 10.1007/s00259-019-04358-9
pii: 10.1007/s00259-019-04358-9
pmc: PMC6647180
doi:
Substances chimiques
(89)Zr-girentuximab
0
Antibodies, Monoclonal
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Deferoxamine
J06Y7MXW4D
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1931-1939Subventions
Organisme : KWF Kankerbestrijding
ID : 2012-5400
Références
Int J Cancer. 2000 Mar 15;85(6):865-70
pubmed: 10709109
N Engl J Med. 2001 Dec 6;345(23):1655-9
pubmed: 11759643
Clin Nephrol. 2002 Jan;57(1):56-62
pubmed: 11837802
Clin Cancer Res. 2003 Feb;9(2):802-11
pubmed: 12576453
Urology. 2003 Feb;61(2):314-9
pubmed: 12597937
Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3953S-60S
pubmed: 14506194
BJU Int. 2007 Sep;100(3):556-60
pubmed: 17608827
J Clin Oncol. 2007 Oct 20;25(30):4757-64
pubmed: 17947723
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Urol. 2009 Aug;182(2):728-34
pubmed: 19539328
J Clin Oncol. 2009 Dec 1;27(34):5794-9
pubmed: 19826129
J Clin Oncol. 2013 Jan 10;31(2):187-94
pubmed: 23213092
Lancet Oncol. 2013 Feb;14(2):141-8
pubmed: 23312463
Eur Urol. 2013 Jun;63(6):1101-6
pubmed: 23453421
Int J Mol Sci. 2013 May 29;14(6):11402-23
pubmed: 23759990
Eur Urol. 2014 Mar;65(3):577-84
pubmed: 23962746
J Urol. 2015 Mar;193(3):776-82
pubmed: 25241004
J Nucl Med. 2015 Jan;56(1):63-9
pubmed: 25476536
Eur Urol. 2016 Feb;69(2):352-60
pubmed: 26382085
Lancet Oncol. 2016 Sep;17(9):1317-24
pubmed: 27498080
Front Oncol. 2016 Sep 06;6:201
pubmed: 27656421
Ann Oncol. 2016 Sep;27(suppl 5):v58-v68
pubmed: 27664262
JAMA Oncol. 2017 Jul 1;3(7):913-920
pubmed: 27787547
Biom J. 2017 Sep;59(5):1016-1034
pubmed: 28464322
Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):4-16
pubmed: 28687866
PLoS One. 2018 Feb 26;13(2):e0193477
pubmed: 29481555
Eur Urol. 2018 Sep;74(3):257-260
pubmed: 29730017